<DOC>
	<DOCNO>NCT03105297</DOCNO>
	<brief_summary>To characterize performance nasal dilator strip lower nasal resistance sleep , promote nasal route breathe reduce sign symptom sleep disorder breathe group chronic nocturnal nasal congestion sufferer report trouble sleep .</brief_summary>
	<brief_title>To Characterize Performance Nasal Dilator Strip Lowering Nasal Resistance During Sleep , Promoting Nasal Route Breathing Reducing Signs Symptoms Sleep Disordered Breathing Group Chronic Nocturnal Nasal Congestion Sufferers Who Report Trouble With Their Sleep .</brief_title>
	<detailed_description>This study baseline-controlled study . This study consist four phase : Screening phase , Baseline phase , 28 day Active phase ( 1 month home treatment usage period sleep laboratory night 7 ( Night 8 ) 28 day ( Night 29 ) treatment ) follow two-night cross-over Nasal resistance phase . Screened participant evaluated sleep disorder breathe PSG variable sleep laboratory night Baseline , 7 28 day house use nasal dilator strip ( Night 8 29 Active phase ) , Day 29 30 ( Night 30 31 Nasal resistance phase ) . Participants wear Nasal dilator strip Active phase . Participants enter Nasal resistance phase study , consist two sleep laboratory night Day 29 30 ( Night 30 31 ) separate approximately two day randomize receive sequence either 'strip'/ ' strip ' 'no strip'/'strip '' .</detailed_description>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<criteria>Nostril type I II ( Interaxial angle 41 degree = type I ; interaxial angle 41 70 degree = type II ) Nasal Congestion : Have chronic nocturnal nasal congestion ( 'always almost always ' ) least last year . Sleep : Reports trouble sleep Allergy/Intolerance : Known suspected intolerance hypersensitivity latex . Known suspected intolerance hypersensitivity study material ( closely relate compound ) , allergy atopic reaction adhesive bandage latex . Subject chronic skin condition eczema face nose . Subject visible open sore , sunburn , irritation face nose immediately prior treatment . Subject severe obstructive sleep apnea/hypopnea syndrome AHI score &lt; 30 events/hour Baseline visit . Subject diagnosis another major sleep disorder ( i.e . primary insomnia , i.e . regularly sleep less 6 hour per night , sleep insufficiency , i.e . sleep &gt; 2 hour nonwork day compare work day , narcolepsy , periodic limb movement disorder ) . Subject nontypical sleep schedule ( e.g . shiftwork ) . Subject plan travel involve timezone change study period . Subject take medication know significant effect sleep . Use substance psychotropic effect property know affect sleep/wake , include limited : neuroleptic , morphine/opioid derivative , sedative antihistamine , stimulant , antidepressant , clonidine , barbiturate , anxiolytic , thalidomide , hypnotic sedative . Use counter sleep promote agent include diphenhydramine , doxylamine , tryptophan , valerian root , kava kava , melatonin , St John 's Wort Alluna . Use counter alertness aid include caffeine guarana . Subject currently use topical nasal decongestant ( nasal spray , drop , etc ) . Subject must discontinue use topical decongestant least 7 day prior Baseline . Subject experience acute upper respiratory tract infection qualification phase Baseline visit . Subject abuse alcohol ( regularly drink 3 drink per day ) recent history ( within last 2 year ) substance alcohol abuse . Regular consumption xanthinecontaining beverage ( i.e . tea , coffee , cola ) comprise usually 5 cup glass per day . Subject positive drug abuse screen result . Subject severe , unstable disease state ( e.g . myocardial infarction , congestive heart failure , diabetes , cirrhosis , cancer , epilepsy , stroke ) , pain syndrome , ( e.g . fibromyalgia ) medical surgical condition place subject unacceptable risk he/she participate study confounds ability interpret data study judgement principal investigator would suitable entry study . Severe nasal obstruction cause structural abnormality render subject unsuitable study opinion investigator , i.e . nasal polyp , severe deviate septum . Subject unwilling videotaped record PSG study . Current Treatment Sleep Disordered Breathing ) Subject currently use device prescribe sleep disordered breathing include Continuous Positive Airway Pressure ( CPAP ) , mandibular advancement device , tongue displacement device . b ) Overthecounter product chin strap , pillow , internal/external nasal dilator acceptable provided usage discontinue least 28 day prior Baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Nasal dilator strip</keyword>
	<keyword>Sleep disorder breathing</keyword>
</DOC>